Nanoviricides, INC

NanoViricides, Inc. announced the pricing of a registered direct offering expected to raise approximately $3.8 million before expenses.

NanoViricides, Inc. has entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC to offer and sell shares of its common stock.

NanoViricides, Inc. announced that its drug candidates, NV-387 and NV-387 with encapsulated Remdesivir, are expected to be effective against the current Ebola virus strain in the Democratic Republic of Congo.

NanoViricides, Inc. has successfully closed a registered direct offering, raising approximately $2 million through the sale of common stock and warrants.

NanoViricides, Inc. stockholders re-elected Anil Diwan as a Class I Director, approved executive compensation, and ratified EisnerAmper, LLP as their independent auditor at the 2025 Annual Meeting.

NanoViricides, Inc. has successfully closed a $6 million registered direct offering and concurrent private placement to fund working capital and general corporate purposes.

NanoViricides reports reduced quarterly net loss and significant progress in its broad-spectrum antiviral drug NV-387, including Phase II approval for MPox, while addressing going concern doubts with recent capital raises.

NanoViricides, Inc. announces its Q3 2025 financial results, highlighting progress in clinical trials for NV-387 and expansion of its antiviral drug pipeline.

NanoViricides, Inc. announces its financial results for the quarter ended December 31, 2024, and provides updates on the clinical development of its lead drug candidate, NV-387, targeting multiple viral infections.

NanoViricides reported a net loss of $3.13 million for the quarter ended September 30, 2024, while advancing its lead drug candidate, NV-387, towards Phase II clinical trials for RSV and MPox.

NanoViricides reports its Q3 2024 financial results and provides an update on its clinical development programs, particularly highlighting the completion of a Phase 1a/1b trial for its lead drug candidate NV-387.

NanoViricides reports its second quarter results, showcasing advancements in its clinical trials for NV-CoV-2 and the broad-spectrum antiviral potential of NV-387.

NanoViricides, Inc. reports progress in broad-spectrum antiviral drug NV-387's clinical development, including Phase Ia/Ib completion, but faces significant financial constraints and a going concern doubt.

NanoViricides, a clinical-stage company, released its 10-K filing, detailing progress in its nanoviricide drug development programs, particularly NV-387, and its financial status.

A recent SEC filing indicates that Milton Boniuk's ownership percentage in Nanoviricides, Inc. has fallen below the reporting threshold due to the company issuing new securities.

Stephenson Fournier, PLLC, a 10% owner of Nanoviricides, Inc. before a reverse split, has reported a decrease in their ownership percentage due to the company issuing new securities.

NanoViricides, Inc. announced its 2025 Annual Meeting of Stockholders to address director re-election, executive compensation, auditor ratification, and provided updates on related party transactions and clinical trials.

NanoViricides, Inc. is holding its annual meeting on December 7, 2024, to vote on director elections, executive compensation, and the ratification of its independent auditor.